Previous close | 24.72 |
Open | 25.48 |
Bid | 22.01 x 100 |
Ask | 22.10 x 200 |
Day's range | 21.79 - 25.48 |
52-week range | 20.67 - 40.89 |
Volume | |
Avg. volume | 1,200,554 |
Market cap | 2.736B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.77 |
Earnings date | 05 Aug 2024 - 09 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 55.38 |
Comprehensive Analysis of ARWR's Fiscal 2024 Q2 Earnings Against Market Forecasts
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript May 9, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and […]
PASADENA, Calif., May 09, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discuss the results.